[1] AKINOSOGLOU K, PAPAGEORGIOU D, GOGOS C, et al. An update on newer antifungals[J]. Expert Rev Anti Infect Ther, 2025, 23(2-4): 149-158. doi:  10.1080/14787210.2025.2461566
[2] SZYMAŃSKI M, CHMIELEWSKA S, CZYŻEWSKA U, et al. Echinocandins–structure, mechanism of action and use in antifungal therapy[J]. J Enzyme Inhib Med Chem, 2022, 37(1): 876-894. doi:  10.1080/14756366.2022.2050224
[3] BERMAN J, KRYSAN D J. Drug resistance and tolerance in fungi[J]. Nat Rev Microbiol, 2020, 18(6): 319-331. doi:  10.1038/s41579-019-0322-2
[4] NOURRISSON C, MONIOT M, LAVERGNE R A, et al. Acquired fluconazole resistance and genetic clustering in Diutina(Candida)catenulata from clinical samples[J]. Clin Microbiol Infect, 2023, 29(2): 257. e7-257. e11.
[5] BÉDARD C, GAGNON-ARSENAULT I, BOISVERT J, et al. Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost[J]. Nat Microbiol, 2024, 9(11): 3025-3040. doi:  10.1038/s41564-024-01819-2
[6] FANDILOLU P, KUMAR C, PALIA D, et al. Investigating role of positively selected genes and mutation sites of ERG11 in drug resistance of Candida albicans[J]. Arch Microbiol, 2024, 206(11): 437. doi:  10.1007/s00203-024-04159-1
[7] ZARE-BIDAKI M, MALEKI A, GHANBARZADEH N, et al. Expression pattern of drug-resistance genes ERG11 and TAC1 in Candida albicans Clinical isolates[J]. Mol Biol Rep, 2022, 49(12): 11625-11633. doi:  10.1007/s11033-022-07878-0
[8] ROJAS A E, CÁRDENAS L Y, GARCÍA M C, et al. Expression of ERG11 ERG3 MDR1 and CDR1 genes in Candida tropicalis[J]. Biomedica, 2023, 43(Sp.1): 144-155. doi:  10.7705/biomedica.6852
[9] YENIŞEHIRLI G, ALıCı A, YENIŞEHIRLI A. Antifungal drug susceptibility profiles and molecular mechanisms of azole resistance in Candida blood stream isolates[J]. Indian J Med Microbiol, 2023, 45: 100389. doi:  10.1016/j.ijmmb.2023.100389
[10] VU B G, SIMONICOVA L, MOYE-ROWLEY W S. Calcineurin is required for Candida glabrata Pdr1 transcriptional activation[J]. mBio, 2023, 14(6): e02416-e02423. doi:  10.1101/2023.07.10.548434
[11] WASEEM M, DAS S, MONDAL D, et al. Identification of novel inhibitors against Med15a KIX domain of Candida glabrata[J]. Int J Biol Macromol, 2023, 253(Pt 2): 126720.
[12] SUCHODOLSKI J, MURASZKO J, KORBA A, et al. Lipid composition and cell surface hydrophobicity of Candida albicans influence the efficacy of fluconazole-gentamicin treatment[J]. Yeast, 2020, 37(1): 117-129. doi:  10.1002/yea.3455
[13] MASSEY J, ZARNOWSKI R, ANDES D. Role of the extracellular matrix in Candida biofilm antifungal resistance[J]. FEMS Microbiol Rev, 2023, 47(6): fuad059. doi:  10.1093/femsre/fuad059
[14] ARASTEHFAR A, DANESHNIA F, HOVHANNISYAN H, et al. A multidimensional assessment of in-host fitness costs of drug resistance in the opportunistic fungal pathogen Candida glabrata[J]. FEMS Yeast Res, 2024, 24: foae035. doi:  10.1093/femsyr/foae035
[15] GÓMEZ-GAVIRIA M, GARCÍA-CARNERO L C, BARUCH-MARTÍNEZ D A, et al. The emerging pathogen Candida metapsilosis: biological aspects, virulence factors, diagnosis, and treatment[J]. Infect Drug Resist, 2024, 17: 171-185. doi:  10.2147/IDR.S448213
[16] BOUTIN C A, LUONG M L. Update on therapeutic approaches for invasive fungal infections in adults[J]. Ther Adv Infect Dis, 2024, 11: 20499361231224980.
[17] RAMOS L S, BARBOSA P F, LORENTINO C M A, et al. The multidrug-resistant Candida auris, Candida haemulonii complex and phylogenetic related species: Insights into antifungal resistance mechanisms[J]. Curr Res Microb Sci, 2025, 8: 100354.
[18] CAROLUS H, PIERSON S, LAGROU K, et al. Amphotericin B and other polyenes: discovery, clinical use, mode of action and drug resistance[J]. J Fungi, 2020, 6(4): 321. doi:  10.3390/jof6040321
[19] SHBETA M, KOPP T, VORONOV I, et al. Fluorescent probes derived from the polyene class of antifungal drugs reveal distinct localization patterns and resistance-associated vacuolar sequestration in Candida Species[J]. Angew Chem Int Ed, 2026, 65(2): e21135. doi:  10.1002/anie.202521135
[20] KE W X, XIE Y Y, CHEN Y Y, et al. Fungicide-tolerant persister formation during cryptococcal pulmonary infection[J]. Cell Host Microbe, 2024, 32(2): 276-289. e7.
[21] BRAUNER A, FRIDMAN O, GEFEN O, et al. Distinguishing between resistance, tolerance and persistence to antibiotic treatment[J]. Nat Rev Microbiol, 2016, 14(5): 320-330. doi:  10.1038/nrmicro.2016.34
[22] DUMEAUX V, MASSAHI S, BETTAUER V, et al. Candida albicans exhibits heterogeneous and adaptive cytoprotective responses to antifungal compounds[J]. eLife, 2023, 12: e81406. doi:  10.7554/eLife.81406
[23] ZHENG L J, XU Y, WANG C, et al. Ketoconazole induces reversible antifungal drug tolerance mediated by trisomy of chromosome R in Candida albicans[J]. Front Microbiol, 2024, 15: 1450557. doi:  10.3389/fmicb.2024.1450557
[24] SAH S K, YADAV A, STAHL T, et al. Echinocandin adaptation in Candida albicans is accompanied by altered chromatin accessibility at gene promoters and by cell wall remodeling[J]. J Fungi, 2025, 11(2): 110. doi:  10.3390/jof11020110
[25] FENG Y R, LU H, WHITEWAY M, et al. Understanding fluconazole tolerance in Candida albicans: implications for effective treatment of candidiasis and combating invasive fungal infections[J]. J Glob Antimicrob Resist, 2023, 35: 314-321. doi:  10.1016/j.jgar.2023.10.019
[26] SUN L L, LI H, YAN T H, et al. Aneuploidy mediates rapid adaptation to a subinhibitory amount of fluconazole in Candida albicans[J]. Microbiol Spectr, 2023, 11(2): e03016-e03022. doi:  10.1128/spectrum.03016-22
[27] YANG F, SCOPEL E F C, LI H, et al. Antifungal tolerance and resistance emerge at distinct drug concentrations and rely upon different aneuploid chromosomes[J]. mBio, 2023, 14(2): e00227-e00223. doi:  10.1101/2022.11.30.518455
[28] ZARNOWSKI R, HORTON M V, JOHNSON C J, et al. Dual function of Candida auris mannosyltransferase, MNT5, in biofilm community protection from antifungal therapy and the host[J]. mBio, 2025, 16(4): e00346-e00325. doi:  10.1128/mbio.00346-25
[29] ADEJOR J, TUMUKUNDE E, LI G Q, et al. Stepping out of the dark: how metabolomics shed light on fungal biology[J]. FEMS Microbiol Rev, 2025, 49: fuaf028. doi:  10.1093/femsre/fuaf028
[30] EL MEOUCHE I, JAIN P, JOLLY M K, et al. Drug tolerance and persistence in bacteria, fungi and cancer cells: Role of non-genetic heterogeneity[J]. Transl Oncol, 2024, 49: 102069. doi:  10.1016/j.tranon.2024.102069
[31] YAU K P S, WEERASINGHE H, OLIVIER F A B, et al. The proteasome regulator Rpn4 controls antifungal drug tolerance by coupling protein homeostasis with metabolic responses to drug stress[J]. PLoS Pathog, 2023, 19(4): e1011338. doi:  10.1371/journal.ppat.1011338
[32] CHEN L, TIAN X Y, ZHANG L Y, et al. Brain glucose induces tolerance of Cryptococcus neoformans to amphotericin B during meningitis[J]. Nat Microbiol, 2024, 9(2): 346-358. doi:  10.1038/s41564-023-01561-1
[33] SU Y Y, LI Y, YI Q L, et al. Insight into the mechanisms and clinical relevance of antifungal heteroresistance[J]. J Fungi, 2025, 11(2): 143. doi:  10.3390/jof11020143
[34] BOJSEN R, REGENBERG B, FOLKESSON A. Persistence and drug tolerance in pathogenic yeast[J]. Curr Genet, 2017, 63(1): 19-22. doi:  10.1007/s00294-016-0613-3
[35] WUYTS J, VAN DIJCK P, HOLTAPPELS M. Fungal persister cells: The basis for recalcitrant infections?[J]. PLoS Pathog, 2018, 14(10): e1007301. doi:  10.1371/journal.ppat.1007301
[36] BICER M. Exploring therapeutic avenues: mesenchymal stem/stromal cells and exosomes in confronting enigmatic biofilm-producing fungi[J]. Arch Microbiol, 2023, 206(1): 11. doi:  10.1007/s00203-023-03744-0
[37] MURANTE D, HOGAN D A. Drivers of diversification in fungal pathogen populations[J]. PLoS Pathog, 2024, 20(9): e1012430. doi:  10.1371/journal.ppat.1012430
[38] AMICH J, BROMLEY M, GOLDMAN G H, et al. Toward the consensus of definitions for the phenomena of antifungal tolerance and persistence in filamentous fungi[J]. mBio, 2025, 16(4): e03475-e03424. doi:  10.1128/mbio.03475-24
[39] CORONA RAMIREZ A, BREGNARD D, JUNIER T, et al. Assessment of fungal spores and spore-like diversity in environmental samples by targeted lysis[J]. BMC Microbiol, 2023, 23(1): 68. doi:  10.1186/s12866-023-02809-w
[40] MOGHADAM S, ZARRINFAR H, NASERI A, et al. Investigating the susceptibility profiles and in vitro combinations of caspofungin, itraconazole, fluconazole, voriconazole, clotrimazole, and amphotericin B against clinical isolates causing fungal keratitis[J]. Diagn Microbiol Infect Dis, 2025, 112(3): 116806. doi:  10.1016/j.diagmicrobio.2025.116806
[41] AN L L, TAN J W, WANG Y Y, et al. Synergistic effect of the combination of deferoxamine and fluconazole in vitro and in vivo against fluconazole-resistant Candida Spp[J]. Antimicrob Agents Chemother, 2022, 66(11): e00725-e00722.
[42] JIN X Y, ZHANG M, LU J H, et al. Hinokitiol chelates intracellular iron to retard fungal growth by disturbing mitochondrial respiration[J]. J Adv Res, 2021, 34: 65-77. doi:  10.1016/j.jare.2021.06.016
[43] SHABAN S, PATEL M, AHMAD A. Fungicidal activity of human antimicrobial peptides and their synergistic interaction with common antifungals against multidrug-resistant Candida auris[J]. Int Microbiol, 2023, 26(2): 165-177. doi:  10.21203/rs.3.rs-1938651/v1
[44] CHEN Y Y, LI Y X, NAHAR K S, et al. New generation modified azole antifungals against multidrug-resistant Candida auris[J]. J Med Chem, 2025, 68(13): 14054-14071. doi:  10.1021/acs.jmedchem.5c01253
[45] LAL K, GROVER A, RAGSHANIYA A, et al. Current advancements and future perspectives of 1, 2, 3-triazoles to target lanosterol 14α-demethylase(CYP51), a cytochrome P450 enzyme: a computational approach[J]. Int J Biol Macromol, 2025, 315(Pt 1): 144240.
[46] PRAJAPATI C, RAI S N, SINGH A K, et al. An update of fungal endophyte diversity and strategies for augmenting therapeutic potential of their potent metabolites: recent advancement[J]. Appl Biochem Biotechnol, 2025, 197(5): 2799-2866. doi:  10.1007/s12010-024-05098-9
[47] WU Y M, JIANG W N, CONG Z H, et al. An effective strategy to develop potent and selective antifungal agents from cell penetrating peptides in tackling drug-resistant invasive fungal infections[J]. J Med Chem, 2022, 65(10): 7296-7311. doi:  10.1021/acs.jmedchem.2c00274
[48] WANG X R, ZHONG H, MA S S, et al. Discovery of petroselinic acid with in vitro and in vivo antifungal activity by targeting fructose-1, 6-bisphosphate aldolase[J]. Phytomedicine, 2024, 133: 155948. doi:  10.1016/j.phymed.2024.155948
[49] ZHOU H, ZHANG J P, WANG R, et al. The unfolded protein response is a potential therapeutic target in pathogenic fungi[J]. FEBS J, 2025, 292(19): 5008-5025. doi:  10.1111/febs.70100
[50] ZHANG L, XIAO J Z, DU M W, et al. Post-translational modifications confer amphotericin B resistance in Candida krusei isolated from a neutropenic patient[J]. Front Immunol, 2023, 14: 1148681. doi:  10.3389/fimmu.2023.1148681
[51] NIKOLOV V N, MALAVIA D, KUBOTA T. SWI/SNF and the histone chaperone Rtt106 drive expression of the Pleiotropic Drug Resistance network genes[J]. Nat Commun, 2022, 13(1): 1968. doi:  10.1038/s41467-022-29591-z
[52] SHANG X X, ZHANG Q, YANG Q L, et al. Do fungi also undergo “ferroptosis”? A microscopic exploration of cellular death[J]. Apoptosis, 2025, 30(11-12): 2495-2510. doi:  10.1007/s10495-025-02164-3
[53] ZHU T B, CHEN X, LI C L, et al. Lanosterol 14α-demethylase(CYP51)/histone deacetylase(HDAC)dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections[J]. Eur J Med Chem, 2021, 221: 113524. doi:  10.1016/j.ejmech.2021.113524
[54] LI Y J, QIAO Y, MA Y Y, et al. AI in fungal drug development: opportunities, challenges, and future outlook[J]. Front Cell Infect Microbiol, 2025, 15: 1610743. doi:  10.3389/fcimb.2025.1610743
[55] GENTILE F, AGRAWAL V, HSING M, et al. Deep docking: a deep learning platform for augmentation of structure based drug discovery[J]. ACS Cent Sci, 2020, 6(6): 939-949. doi:  10.1021/acscentsci.0c00229
[56] SONG D H, LIU H M, HUANG Y K, et al. High-throughput monitoring of pathogenic fungal growth using whole slide imaging for rapid antifungal susceptibility assessment[J]. Anal Lett, 2024, 57(15): 2412-2425. doi:  10.1080/00032719.2023.2297301